TABLE 1.
Clinical and molecular features of 586 patients with lung adenocarcinoma (LUAD) included in this study.
| Features | Median (IR)* | N (%)† |
| Age at tumor diagnosis, years | 67 (16) | – |
| Gender | ||
| Male | 271 (46.2) | |
| Female | 315 (53.8) | |
| Histological subtype | 72 (12.3) | |
| Acinar | 47 (65.3) | |
| Lepidic | 25 (34.7) | |
| Patients tested for somatic alterations‡ | 502 (85.7)‡ | |
| EGFR mutation | 106 (21.1) | |
| KRAS mutation | 148 (29.5) | |
| BRAF mutation | ||
| None | 233 (46.4) | |
| Carriers of TP53 c.1010G>A (p.Arg337His)§ | 7 (1.2)§ | |
*IR, interquartile range.
†The percentage was calculated over the total number of genotyped samples (586) and over the number of cases for which the specified clinical data was available.
‡Tested for somatic EGFR, KRAS, BRAF, and NRAS mutations. Specific regions evaluated in each gene are detailed in the “Materials and Methods.
”§ Seven carriers were identified using TaqMan® assays, but heterozygous genotype was confirmed by NGS in only five positive cases due to limitations in sample availability for the remaining two patients.